MANE
Veradermics, Incorporated
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+30/100
Last price
109.76
▼ 9.11 (7.66%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
110.90
Prev close
118.87
Day high
119.00
Day low
108.79
Volume
736.52K
Market cap
$4.55B
P/E (TTM)
—
52W range
32.00 – 131.24
Day trading desk
Gap from prior close
-6.70%
Prior close 118.87
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
1.04%
109.76 – 110.90
Position in range
0%
Near session low
ATR (14D)
6.73
6.13% of price
Prior day high
119.12
PDH
Prior day low
114.80
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 725.23K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-7.52%
-9.5%
1M
+10.61%
+9.5%
3M
-7.86%
-12.4%
6M
+92.14%
+74.0%
YTD
+188.64%
+174.4%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on MANE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-654.10K
Net selling
Buy transactions
3
306.90K shares
Sell transactions
4
961.00K shares
Net transactions
+7
Buys less sells
Sell : buy shares
3.1 : 1
Mixed
Insider-held shares
1.04M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 20, 26 | SUVRETTA CAPITAL MANAGEMENT, LLC Unknown |
— | 300.00K | — | Indirect |
| Aug 19, 26 | SUVRETTA CAPITAL MANAGEMENT, LLC Unknown |
SELL | 750.00K | $80.44M | Indirect |
| Aug 17, 26 | DURSO TIMOTHY AUGUST Chief Technology Officer |
CONVERSION | 3.45K | $42.08K | Direct |
| Aug 17, 26 | WALDMAN REID ALEXANDER M.D. Chief Executive Officer |
CONVERSION | 3.45K | $42.08K | Direct |
| Aug 17, 26 | DURSO TIMOTHY AUGUST Chief Technology Officer |
SELL | 43.50K | $4.69M | Direct |
| Aug 17, 26 | WALDMAN REID ALEXANDER M.D. Chief Executive Officer |
SELL | 67.50K | $7.28M | Direct |
| Aug 12, 26 | CHILDS JOHN W Director |
SELL | 100.00K | $10.71M | Indirect |
| Feb 6, 26 | SUVRETTA CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 282.67K | $10.54M | Indirect |
| Feb 5, 26 | CHILDS JOHN W Director |
BUY | 294.12K | $10.93M | Indirect |
| Feb 5, 26 | CHILDS JOHN W Director |
BUY | 294.12K | $10.93M | Indirect |
| Feb 5, 26 | ENRIGHT PATRICK G. Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.07M | $40.58M | Indirect |
| Feb 5, 26 | CORIC VLADIMIR Director |
BUY | 117.65K | $4.37M | Indirect |
| Feb 5, 26 | LONGITUDE CAPITAL PARTNERS V, LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.07M | $39.95M | Indirect |
| Feb 5, 26 | CHILDS JOHN W Director |
— | 1.91M | — | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHILDS JOHN W |
Director | — | Sale |
CORIC VLADIMIR |
Director | — | Purchase |
DURSO TIMOTHY AUGUST |
Chief Technology Officer | 78.14K | Conversion of Exercise of derivative security |
ENRIGHT PATRICK G. |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
GRANT-KELS JANE M. M.D. |
Director | 2.46K | Conversion of Exercise of derivative security |
LONGITUDE CAPITAL PARTNERS V, LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
SUVRETTA CAPITAL MANAGEMENT, LLC |
Unknown | — | Conversion of Exercise of derivative security |
WALDMAN REID ALEXANDER M.D. |
Chief Executive Officer | 170.82K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$4.55B
Enterprise value$3.73B
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-104.29M
EPS (TTM)$-4.24
Free cash flow—
Total cash$819.89M
Total debt$428.00K
Book value / share$19.47
Shares outstanding41.78M
Float32.29M
Short % of float15.09%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-40.55
PEG ratio—
Price / sales—
Price / book5.60
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity0.05
Current ratio70.53
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | — |
| Research & development | $62.06M | $23.28M | $14.97M | +166.6% |
| Selling, general & admin | $10.28M | $3.50M | $2.35M | +194.2% |
| Total operating expense | $71.56M | $26.38M | $17.32M | +171.2% |
| Operating income | -$71.56M | -$26.38M | -$17.32M | -171.2% |
| Net interest income | $1.56M | -$104.00K | $834.00K | +1,601.9% |
| Pre-tax income | -$70.00M | -$26.49M | -$16.49M | -164.3% |
| Tax provision | $0 | $0 | $0 | — |
| Net income | -$70.00M | -$26.49M | -$16.49M | -164.3% |
| Net income to common | -$83.37M | -$27.30M | -$16.49M | -205.4% |
| Basic EPS | -2.38 | -1.37 | -1.51 | -73.3% |
| Diluted EPS | -2.38 | -1.37 | -1.51 | -73.3% |
| EBIT | -$70.00M | -$25.90M | -$16.45M | -170.2% |
| EBITDA | -$70.00M | -$25.90M | -$16.45M | -170.2% |
| Basic shares | 35.08M | 19.91M | 13.80M | +76.2% |
| Diluted shares | 35.08M | 19.91M | 13.80M | +76.2% |
| Line item | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $21.77M | $53.08M | $16.30M | -59.0% |
| Cash & short-term investments | $141.86M | $53.08M | $16.30M | +167.2% |
| Total current assets | $152.49M | $55.53M | $17.56M | +174.6% |
| Property, plant & equipment | $125.00K | $0 | — | — |
| Total assets | $152.62M | $55.53M | $17.56M | +174.8% |
| Total current liabilities | $9.15M | $4.72M | $3.05M | +94.0% |
| Long-term debt | — | — | $786.00K | — |
| Total debt | $4.00K | $0 | $786.00K | — |
| Total liabilities | $273.63M | $104.02M | $39.80M | +163.1% |
| Retained earnings | -$123.42M | -$49.23M | -$22.74M | -150.7% |
| Shareholder equity | -$121.01M | -$48.48M | -$22.24M | -149.6% |
| Working capital | $143.34M | $50.82M | $14.51M | +182.1% |
| Net tangible assets | -$121.01M | -$48.48M | -$22.24M | -149.6% |
| Shares issued | 37.34M | 35.08M | 35.08M | +6.5% |
| Line item | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|
| Net income | -$70.00M | -$26.49M | -$16.49M | -164.3% |
| Stock-based compensation | $1.44M | $250.00K | $206.00K | +476.0% |
| Change in working capital | -$3.89M | $732.00K | $920.00K | -630.9% |
| Operating cash flow | -$71.60M | -$23.69M | -$13.51M | -202.3% |
| Capital expenditure | -$24.00K | — | — | — |
| Investing cash flow | -$118.86M | $0 | — | — |
| Financing cash flow | $159.14M | $60.48M | $13.89M | +163.1% |
| Free cash flow | -$71.63M | -$23.69M | -$13.51M | -202.4% |
| End cash position | $21.77M | $53.08M | $16.30M | -59.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $18.61M | $20.93M | $18.19M | $18.10M | $14.33M | — | -11.1% |
| Selling, general & admin | $10.95M | $8.94M | $4.82M | $2.25M | $1.74M | — | +22.5% |
| Total operating expense | $29.55M | $29.71M | $22.75M | $19.82M | $16.07M | — | -0.5% |
| Operating income | -$29.55M | -$29.71M | -$22.75M | -$19.82M | -$16.07M | — | +0.5% |
| Net interest income | $4.84M | $2.48M | $906.00K | $71.00K | $103.00K | — | +95.0% |
| Pre-tax income | -$23.50M | -$27.23M | -$21.85M | -$20.10M | -$15.64M | — | +13.7% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$23.50M | -$27.23M | -$21.85M | -$20.10M | -$15.64M | — | +13.7% |
| Net income to common | -$23.50M | -$30.01M | -$28.21M | -$22.57M | -$18.01M | — | +21.7% |
| Basic EPS | -0.58 | -1.32 | -0.62 | — | -0.51 | -0.73 | +56.1% |
| Diluted EPS | -0.58 | -1.32 | -0.62 | — | -0.51 | -0.73 | +56.1% |
| EBIT | -$29.55M | -$29.71M | -$21.85M | -$19.16M | -$16.07M | — | +0.5% |
| EBITDA | -$29.55M | -$29.71M | -$21.85M | -$19.16M | -$16.07M | — | +0.5% |
| Basic shares | 40.44M | 22.70M | 35.08M | — | 35.08M | 19.91M | +78.1% |
| Diluted shares | 40.44M | 22.70M | 35.08M | — | 35.08M | 19.91M | +78.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $319.33M | $168.41M | $21.77M | $5.66M | +89.6% |
| Cash & short-term investments | $819.89M | $390.80M | $141.86M | $15.14M | +109.8% |
| Total current assets | $824.75M | $397.07M | $152.49M | $18.71M | +107.7% |
| Property, plant & equipment | $989.00K | $287.00K | $125.00K | $84.00K | +244.6% |
| Total assets | $825.74M | $397.36M | $152.62M | $18.80M | +107.8% |
| Total current liabilities | $11.69M | $6.72M | $9.15M | $5.69M | +74.1% |
| Total debt | $428.00K | $0 | $4.00K | $16.00K | — |
| Total liabilities | $12.12M | $6.72M | $273.63M | $114.81M | +80.5% |
| Retained earnings | -$174.16M | -$150.65M | -$123.42M | -$97.38M | -15.6% |
| Shareholder equity | $813.61M | $390.64M | -$121.01M | -$96.02M | +108.3% |
| Working capital | $813.05M | $390.35M | $143.34M | $13.02M | +108.3% |
| Net tangible assets | $813.61M | $390.64M | -$121.01M | -$96.02M | +108.3% |
| Shares issued | 41.78M | 37.34M | 37.34M | 35.08M | +11.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$23.50M | -$27.23M | -$21.85M | -$20.10M | -$15.64M | — | +13.7% |
| Stock-based compensation | $3.52M | $5.26M | $974.00K | $138.00K | $115.00K | — | -33.1% |
| Change in working capital | $4.81M | $251.00K | -$2.60M | $559.00K | -$368.00K | — | +1,814.7% |
| Operating cash flow | -$14.49M | -$21.17M | -$23.63M | -$19.01M | -$15.64M | — | +31.5% |
| Capital expenditure | — | — | -$5.00K | — | — | -$19.00K | — |
| Investing cash flow | -$277.29M | -$101.30M | -$109.78M | $15.00M | -$8.33M | — | -173.7% |
| Financing cash flow | $442.70M | $269.11M | $149.51M | $1.08M | $129.00K | — | +64.5% |
| Free cash flow | -$14.51M | -$21.17M | -$23.63M | -$19.01M | -$15.64M | — | +31.4% |
| End cash position | $319.33M | $168.41M | $21.77M | $5.66M | $8.60M | — | +89.6% |
Options analytics
Put / call volume
19.86
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
70.00
-35.8% from spot
ATM implied vol
1.6%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
51
Contracts, this expiry
Put volume
1.01K
Contracts, this expiry
Heaviest call OI
80.00
0 contracts
Heaviest put OI
70.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.64 | -0.58 | +9.6% |
| Mar 2026 | -0.85 | — | — |
| Dec 2025 | -18.24 | -104.54 | -473.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.59 | 5 | $0 | — |
| Next quarter | -0.61 | 5 | $0 | 0.0% |
| Current year | -2.87 | 5 | $0 | 0.0% |
| Next year | -2.69 | 5 | $8.66M | 0.0% |
Analyst targets & ownership
Mean target$163.50
High target$182.00
Low target$135.00
Implied upside48.96%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy1 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders2.49%
Held by institutions98.39%
Institutions holding226
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
116.39
-5.70% from price
SMA 20
110.75
-1.62% from price
SMA 50
107.54
+1.33% from price
SMA 100
107.33
+2.27% from price
SMA 200
—
—
EMA 12
114.21
-3.90% from price
EMA 26
111.14
-1.24% from price
EMA 50
108.75
+0.93% from price
RSI (14)
47.5
Neutral
MACD (12,26,9)
3.07
Hist 0.08
ATR (14)
6.73
6.18% of price
Realised vol 30D
49.7%
Annualised
Bollinger upper
125.63
20, 2σ
Bollinger lower
95.88
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.89
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
49.7%
Annualised
Market vol 1Y
13.4%
SPY, annualised
Max drawdown 1Y
-24.8%
Peak to trough
Max drawdown 5Y
-24.8%
Peak to trough
ATR 14
6.73
6.18% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
4.11M
Prior 4.01M
Change vs prior
+2.4%
Shorts adding
% of float
15.09%
Elevated
% of shares out
9.83%
Against total outstanding
Days to cover
7.1
Crowded exit
Float
32.29M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 16, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jul 15, 26 | Needham | MAINTAINED | Buy | Buy |
| Jul 15, 26 | B. Riley Securities | INITIATED | — | Buy |
| Jul 7, 26 | Jefferies | MAINTAINED | Buy | Buy |
| Jun 16, 26 | LifeSci Capital | INITIATED | — | Outperform |
| Jun 2, 26 | Needham | INITIATED | — | Buy |
| May 18, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Apr 22, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Mar 2, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Mar 2, 26 | Citigroup | INITIATED | — | Buy |
| Mar 2, 26 | Leerink Partners | INITIATED | — | Outperform |
| Mar 2, 26 | Jefferies | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-11
Offering Registrations
S-1 · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-07-15
Additional Forms
D · 2026-05-15
Periodic Financial Reports
10-Q · 2026-05-12
Corporate Changes & Voting Matters
8-K · 2026-05-01
Offering Registrations
S-1MEF · 2026-04-29
Offering Registrations
S-1 · 2026-04-27
Headlines
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
Insider Monkey · 25d ago
Veradermics to Present at Upcoming September Investor Conferences
Business Wire · 33d ago
Veradermics (MANE) Stock Looks Overvalued After Its 161% Rally
Simply Wall St. · 34d ago
Is Veradermics (MANE) Still Undervalued After Its 161% Year To Date Run?
Simply Wall St. · 34d ago
Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade
BeInCrypto · 37d ago
Veradermics Insider Sold Shares Worth $10,711,700, According to a Recent SEC Filing
MT Newswires · 51d ago
Veradermics: Q2 Earnings Snapshot
Associated Press · 56d ago
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Business Wire · 57d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.